Retrospective Cohort Study
Copyright ©The Author(s) 2020.
World J Orthop. Jan 18, 2020; 11(1): 36-46
Published online Jan 18, 2020. doi: 10.5312/wjo.v11.i1.36
Table 1 Modified Musculoskeletal Infection Society criteria for periprosthetic joint infection definition[3]
Two or more positive periprosthetic cultures with phenotypically identical organisms, or
A sinus tract communicating with the joint, or
Having at least three of the following minor criteria:
Elevated serum C-reactive protein > 10 mg/L AND erythrocyte sedimentation rate > 30 mm/h;
Elevated synovial fluid white blood cell count 3.000 cells/μL OR ++ result on leukocyte esterase test strip;
Elevated synovial fluid polymorphonuclear neutrophil percentage (PMN%) > 80%;
Positive histological analysis of periprosthetic tissue;
A single positive culture.
Table 2 European Bone and Joint Infection Society criteria for periprosthetic joint infection definition. One or more criteria fulfilled means positive periprosthetic joint infection diagnosis[4]
Sinus tract OR purulence around the prosthesis;
Acute inflammation on histopathology of periprosthetic tissue;
Elevated synovial fluid white blood cell count of more than 2.000 cells/μL OR elevated synovial fluid polymorphonuclear neutrophil percentage (PMN%) > 70%;
Microbial growth in synovial fluid OR > 2 tissue samples (for highly virulent microorganisms already one positive sample confirms infection) OR sonication fluid (≥ 50 CFU/mL).
Table 3 New 2018 International Consensus Meeting scoring criteria for periprosthetic joint infectiondefinition[5]: Major criteria (at least one of the following)
Two positive cultures of the same organismInfected
Sinus tract with evidence of communication to the joint or visualization of the prosthesis
Table 4 New 2018 International Consensus Meeting scoring criteria for periprosthetic joint infection definition[5]: Preoperative diagnosis
Preoperative score: Minor criteriaScoreDecision
Serum: Elevated CRP or D-Dimer2≥ 6: Infected
Serum: Elevated ESR1
Synovial: Elevated synovial WBC count or LE32-5: Possibly infected1
Synovial: Positive alpha-defensin3
Synovial: Elevated synovial PMN (%)20-1: Not infected
Synovial: Elevated synovial CRP1
Table 5 New 2018 International Consensus Meeting scoring criteria for periprosthetic joint infection definition[5]: Intraoperatieve diagnosis
Inconclusive preoperative score1or dry tapScoreDecision
Preoperative score-≥ 6: Infected; 4-5: Inconclusive; 0-3: Not infected
Positive histology3
Positive purulence3
Single positive culture2
Table 6 Demographics of the described cohort and the group of excluded patients (no alpha-defensin lateral flow test performed)
CohortExcluded
Total (n)5231
Age [mean (SD), yr]72 (9.2)67.5 (9.5)
Gender (n)
Male2412
Female2819
Operated side (n)
Right2812
Left2419
Prosthesis (n)
Total hip arthroplasty4626
Hemi-arthroplasty65
Articulation (n)
MoP3118
CoP84
CoC43
MoM31
HA65
Time to aspiration [Median (range), mo]35 (3-266)32.4 (3-191)
Table 7 Characteristics of all patients with positive alpha-defensin lateral flow test and/or positive or inconclusive criteria
CaseCriteria
A
B
C
D
E
F
G
H
I
PJI?
ArtSinus tractVisible purulenceCRP (mg/ L)ESR (mm/h)WBC count (cells/μL)PMN%Culture synovial fluid (nr of cultures)Culture tissue (nr of cultures)ADMSIS (+/-; criteria)EBJIS (+/-; criteria)2018 ICM (+/-/i; criteria)Revision surgery1- or 2-stage
1CoC--6.521.01910091neg (1)neg (6)+-E,F+E,F+E,F,IYes2-stage
2MoPYes-9.023.0--pos (2)pos (8/9)++A,G,H+A,G,H+A,G,H,IYes2-stage
3MoP--8.529.030004neg (2)---+E-No-
4MoP--9.816.0620077neg (2)pos (5/8)++E,H+E,F,H+E,H,IYes2-stage
5CoC--6.910.02300-neg (1)---+E-No-
6MoP--12.026.010-neg (2)pos (1/2)--C,H-iC,HYes1-stage
7MoP----9350-neg (1)---E+E-ENo-
8HA------neg (1)pos (1/6)+-H-iH,IYes1-stage
9MoP--144.064.03730092pos (1/2)pos (2/6)++C,D,E,F,G,H+E,F,G,H+C,D,E,F,H,IYesDAIR
10MoP--61.072.0790095pos (1/1)pos (9/9)++C,D,E,F,G,H+E,F,G,H+C,D,E,F,H,IYes2-stage
11MoP--71.055.03530097pos (2/2)pos (7/7)++C,D,E,F,G,H+E,F,G,H+C,D,E,F,H,IYes2-stage
12HA--9.6-490081--+-E,F+E,F+E,F,INo-
13MoM-Yes195.0-26400096neg (2)-++B,C,E,F+B,E,F+B,C,E,F,INo-
14MoP--15.013.08000-neg (1)neg (6)+-C,E+E+C,E,IYes2-stage
15HA--1.09.0400015neg (2)---E+E-ENo-
16MoM--5.78.0517052neg (3)-+-E+E+E,INo-
Table 8 All cases of positive cultures in the described cohort
CaseCulture after aspiration (positive cultures/nr of total cultures)Culture after revision (positive cultures/nr of total cultures)
2Propionibacterium acnes (2/2)Cutibacterium acnes (8/9)
Staphylococcus aureus (1/2)
4Negative (2/2)Staphylococcus capitis (5/8)
Staphyloccus hominis (1/8)
Staphylococcus epidermidis (1/8)
Propionibacterium acnes (1/8)
7Negative (2/2)Propionibacterium acnes (1/2)
8Negative (1/1)Staphylococcus capitis (1/6)
9Staphylococcus aureus (1/2)Staphylococcus aureus (2/6)
10Pseudomonas aeruginosa (1/1)Pseudomonas aeruginosa (9/9)
Staphylococcus epidermidis (1/9)
13Staphylococcus lugdunensis (2/2)Staphylococcus lugdunensis (7/7)